RFP_AHRQ-16-10013_-_Attachment_G_-_Tables_on_Length_of_Stay_and_Mortality _and_Patient_Characteristics.pdf

Attachment G

Tables on Length of Stay and Mortality, and Patient Characteristics

(Four examples of tables indicating the length of stay and inpatient mortality for each example MPSMS measure, and four examples of tables providing demographic, comorbidities, and other information about patients exposed to the example MPSMS measures, with columns summarizing information on the patients that did and did not experience adverse events.)

2014 MPSMS Annual Report of 2013 Data: Outcomes 12/2014

Cases Estimate 95% CI Cases Estimate 95% CI 218 7,106

Length of stay* (mean, days) 191 13.03 11.52-14.54 6,675 5.66 5.54-5.79 In-hospital mortality (%) 23 10.55 6.81-15.41 428 6.02 5.48-6.6

*Excluded > 60 days and in-hospital mortality

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings

Outcomes

Catheter-Associated Urinary Tract Infections (CAUTI) 7,324 Eligible Cases

Patients who had at least one Adverse Event Patients without an Adverse Event

Hospital Discharges January 2013 - December 2013

Cases Estimate 95% CI Cases Estimate 95% CI 127 2,391

Length of stay* (mean, days) 97 12.82 10.94-14.71 2,353 5.68 5.47-5.9 In-hospital mortality (%) 26 20.47 13.83-28.54 38 1.59 1.13-2.17

*Excluded > 60 days and in-hospital mortality

Patients who had at least one Adverse Event Patients without an Adverse Event

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings

Outcomes

2,518 Eligible Cases

Adverse Events Associated with Warfarin

Cases Estimate 95% CI Cases Estimate 95% CI 25 5,019

Length of stay* (mean, days) 25 14.72 11.57-17.87 4,927 5.4 5.24-5.55 In-hospital mortality (%) 0 0 0.00-13.72 87 1.73 1.39-2.13

*Excluded > 60 days and in-hospital mortality

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings

Outcomes

Postoperative Venous Thromboembolic Events (VTE) 5,044 Eligible Cases

Patients who had at least one Adverse Patients without an Adverse Event

Cases Estimate 95% CI Cases Estimate 95% CI 693 17,259

Length of stay* (mean, days) 595 11.43 10.69-12.16 16,576 4.63 4.56-4.69 In-hospital mortality (%) 90 12.99 10.57-15.72 678 3.93 3.64-4.23

*Excluded > 60 days and in-hospital mortality

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings

Outcomes

Patients who had at least one Adverse Event Patients without an Adverse Event

Hospital-Acquired Pressure Ulcers (HAPU) 17,952 Eligible Cases

2014 MPSMS Annual Report of 2013 Data: Patient Characteristics 12/2014

Patients Exposed

Patients with Adverse Event Rate 95% CI

Total 7,324 218 2.98 2.6-3.39

Age:

<65 2,909 54 1.86 1.4-2.42 65-74 1,803 58 3.22 2.45-4.14 75-84 1,524 59 3.87 2.96-4.97 85 and over 1,088 47 4.32 3.19-5.7

Gender:

Female 4,252 137 3.22 2.71-3.8 Male 3,072 81 2.64 2.1-3.27

Race/Ethnicity:

White-non-hispanic 5,758 166 2.88 2.47-3.35 Black-non-hispanic 799 33 4.13 2.86-5.75 Hispanic 421 13 3.09 1.65-5.22 Asian 138 4 2.9 0.8-7.26 American Indian/Alaska Native 48 1 2.08 0.05-11.07 Native Hawaiian/Pacific Islander 6 0 0 0.00-45.93 Other 154 1 0.65 0.02-3.56

Diabetes:

Yes 2,435 94 3.86 3.13-4.7 No 4,889 124 2.54 2.11-3.02 Obesity:

Yes 2,344 74 3.16 2.49-3.95 No 4,980 144 2.89 2.44-3.4 Cerebrovascular Disease:

Yes 1,135 58 5.11 3.9-6.56 No 6,189 160 2.59 2.2-3.01 CHF/Pulmonary Edema:

Yes 2,642 119 4.5 3.75-5.37 No 4,682 99 2.11 1.72-2.57

COPD:

Yes 1,976 72 3.64 2.86-4.57 No 5,348 146 2.73 2.31-3.2 Smoking:

Yes 1,701 36 2.12 1.49-2.92 No 5,623 182 3.24 2.79-3.73 Corticosteroids:

Yes 446 15 3.36 1.89-5.49 No 6,878 203 2.95 2.56-3.38 Coronary Artery Disease:

Yes 3,058 132 4.32 3.62-5.1 No 4,266 86 2.02 1.62-2.48 Renal Disease:

Yes 1,991 113 5.68 4.7-6.78 No 5,333 105 1.97 1.61-2.38

Adverse Event Rate % of exposed with event

Catheter-Associated Urinary Tract Infections (CAUTI) (N = 7,324)

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings

Patient Characteristics

Exposed

Patients with Adverse Event Rate 95% CI

Total 2,518 127 5.04 4.22-5.97

Age:

<65 673 31 4.61 3.15-6.47 65-74 672 28 4.17 2.79-5.97 75-84 729 39 5.35 3.83-7.24 85 and over 444 29 6.53 4.42-9.25

Gender:

Female 1,271 69 5.43 4.25-6.82 Male 1,247 58 4.65 3.55-5.97

Race/Ethnicity:

White-non-hispanic 2,098 100 4.77 3.89-5.77 Black-non-hispanic 232 14 6.03 3.34-9.92 Hispanic 108 6 5.56 2.07-11.7 Asian 32 4 12.5 3.51-28.99 American Indian/Alaska Native 9 1 11.11 0.28-48.25 Native Hawaiian/Pacific Islander 2 0 0 0.00-84.19 Other 37 2 5.41 0.66-18.19

Diabetes:

Yes 1,045 58 5.55 4.24-7.12 No 1,473 69 4.68 3.66-5.89 Obesity:

Yes 901 42 4.66 3.38-6.25 No 1,617 85 5.26 4.22-6.46 Cerebrovascular Disease:

Yes 539 38 7.05 5.04-9.55 No 1,979 89 4.5 3.63-5.51 CHF/Pulmonary Edema:

Yes 1,502 83 5.53 4.43-6.8 No 1,016 44 4.33 3.16-5.77

COPD:

Yes 880 60 6.82 5.24-8.69 No 1,638 67 4.09 3.18-5.17 Smoking:

Yes 461 24 5.21 3.36-7.65 No 2,057 103 5.01 4.11-6.04 Corticosteroids:

Yes 188 16 8.51 4.94-13.45 No 2,330 111 4.76 3.93-5.71 Coronary Artery Disease:

Yes 1,320 85 6.44 5.18-7.9 No 1,198 42 3.51 2.54-4.71 Renal Disease:

Yes 956 62 6.49 5.01-8.24 No 1,562 65 4.16 3.23-5.27

Adverse Event Rate % of exposed with event

Adverse Events Associated with Warfarin (N = 2,518)

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings Hospital Discharges January 2013 - December 2013

Exposed

Patients with Adverse Event Rate 95% CI

Total 17,952 693 3.86 3.58-4.15

Age:

<65 6,819 150 2.2 1.86-2.58 65-74 4,263 150 3.52 2.99-4.12 75-84 3,930 195 4.96 4.3-5.69 85 and over 2,940 198 6.73 5.86-7.7

Gender:

Female 9,318 385 4.13 3.74-4.56 Male 8,634 308 3.57 3.19-3.98

Race/Ethnicity:

White-non-hispanic 13,848 558 4.03 3.71-4.37 Black-non-hispanic 2,140 71 3.32 2.6-4.17 Hispanic 1,131 34 3.01 2.09-4.18 Asian 341 14 4.11 2.26-6.79 American Indian/Alaska Native 142 8 5.63 2.46-10.8 Native Hawaiian/Pacific Islander 19 0 0 0.00-17.65 Other 331 8 2.42 1.05-4.71

Diabetes:

Yes 6,675 339 5.08 4.56-5.63 No 11,277 354 3.14 2.83-3.48 Obesity:

Yes 5,320 194 3.65 3.16-4.19 No 12,632 499 3.95 3.62-4.3 Cerebrovascular Disease:

Yes 2,906 168 5.78 4.96-6.69 No 15,046 525 3.49 3.2-3.79 CHF/Pulmonary Edema:

Yes 7,952 426 5.36 4.87-5.87 No 10,000 267 2.67 2.36-3.01

COPD:

Yes 5,560 310 5.58 4.99-6.21 No 12,392 383 3.09 2.79-3.41 Smoking:

Yes 4,575 131 2.86 2.4-3.39 No 13,377 562 4.2 3.87-4.56 Corticosteroids:

Yes 1,281 72 5.62 4.42-7.03 No 16,671 621 3.73 3.44-4.02 Coronary Artery Disease:

Yes 9,375 382 4.07 3.68-4.49 No 8,577 311 3.63 3.24-4.04 Renal Disease:

Yes 5,571 351 6.3 5.68-6.97 No 12,381 342 2.76 2.48-3.07

Adverse Event Rate % of exposed with event

Hospital-Acquired Pressure Ulcers (HAPU) (N = 17,952)

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings

Exposed

Patients with Adverse Event Rate 95% CI

Total 5,044 25 0.5 0.32-0.73

Age:

<65 2,564 13 0.51 0.27-0.87 65-74 1,349 6 0.44 0.16-0.97 75-84 849 3 0.35 0.07-1.03 85 and over 282 3 1.06 0.22-3.08

Gender:

Female 2,987 11 0.37 0.18-0.66 Male 2,057 14 0.68 0.37-1.14

Race/Ethnicity:

White-non-hispanic 3,998 21 0.53 0.33-0.8 Black-non-hispanic 507 3 0.59 0.12-1.72 Hispanic 306 1 0.33 0.01-1.81 Asian 83 0 0 0.00-4.35 American Indian/Alaska Native 21 0 0 0.00-16.11 Native Hawaiian/Pacific Islander 1 0 0 0.00-97.5 Other 128 0 0 0.00-2.84

Diabetes:

Yes 1,272 9 0.71 0.32-1.34 No 3,772 16 0.42 0.24-0.69 Obesity:

Yes 1,756 11 0.63 0.31-1.12 No 3,288 14 0.43 0.23-0.71 Cerebrovascular Disease:

Yes 474 4 0.84 0.23-2.15 No 4,570 21 0.46 0.28-0.7 CHF/Pulmonary Edema:

Yes 497 5 1.01 0.33-2.33 No 4,547 20 0.44 0.27-0.68

COPD:

Yes 711 5 0.7 0.23-1.63 No 4,333 20 0.46 0.28-0.71 Smoking:

Yes 1,149 7 0.61 0.25-1.25 No 3,895 18 0.46 0.27-0.73 Corticosteroids:

Yes 161 0 0 0.00-2.27 No 4,883 25 0.51 0.33-0.75 Coronary Artery Disease:

Yes 1,308 13 0.99 0.53-1.69 No 3,736 12 0.32 0.17-0.56 Renal Disease:

Yes 631 6 0.95 0.35-2.06 No 4,413 19 0.43 0.26-0.67

Adverse Event Rate % of exposed with event

Postoperative Venous Thromboembolic Events (VTE) (N = 5,044)

Medicare Patient Safety Monitoring System Annual Data Report: 2013 Findings